Home LiteratureArticle Details
PMID: 17710230 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

The Journal of clinical investigation ·Vol. 117 ·No. 9 ·2007-09-00 ·Pages 2570-82

Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH

Abstract

A small population of plasmacytoid DCs (pDCs) in mouse tumor-draining LNs can express the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). We show that these IDO+ pDCs directly activate resting CD4+CD25+Foxp3+ Tregs for potent suppressor activity. In vivo, Tregs isolated from tumor-draining LNs were constitutively activated and suppressed antigen-specific T cells immediately ex vivo. In vitro, IDO+ pDCs from tumor-draining LNs rapidly activated resting Tregs from non-tumor-bearing hosts without the need for mitogen or exogenous anti-CD3 crosslinking. Treg activation by IDO+ pDCs was MHC restricted, required an intact amino acid-responsive GCN2 pathway in the Tregs, and was prevented by CTLA4 blockade. Tregs activated by IDO markedly upregulated programmed cell death 1 ligand 1 (PD-L1) and PD-L2 expression on target DCs, and the ability of Tregs to suppress target T cell proliferation was abrogated by antibodies against the programmed cell death 1/PD-L (PD-1/PD-L) pathway. In contrast, Tregs activated by anti-CD3 crosslinking did not cause upregulation of PD-Ls, and suppression by these cells was unaffected by blocking the PD-1/PD-L pathway. Tregs isolated from tumor-draining LNs in vivo showed potent PD-1/PD-L-mediated suppression, which was selectively lost when tumors were grown in IDO-deficient hosts. We hypothesize that IDO+ pDCs create a profoundly suppressive microenvironment within tumor-draining LNs via constitutive activation of Tregs.

MeSH Terms
Animals B7-1 Antigen/metabolism B7-H1 Antigen Cell Differentiation Dendritic Cells/cytology,enzymology,immunology Histocompatibility Antigens/immunology Humans Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism Ligands Lymph Nodes/cytology,immunology Lymphatic Metastasis Lymphocyte Activation/immunology Membrane Glycoproteins/metabolism Mice Neoplasm Transplantation Peptides/metabolism Signal Transduction T-Lymphocytes, Regulatory/cytology,immunology
Chemicals
B7-1 Antigen B7-H1 Antigen Cd274 protein, mouse Histocompatibility Antigens Indoleamine-Pyrrole 2,3,-Dioxygenase Ligands Membrane Glycoproteins Peptides
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Sharma Madhav D
Department of Pediatrics, School of Medicine, Medical College of Georgia, Augusta, Georgia 30912, USA.
Baban Babak
Chandler Phillip
Hou De-Yan
Singh Nagendra
Yagita Hideo
Azuma Miyuki
Blazar Bruce R
Mellor Andrew L
Munn David H
References (51)
51 references, click to expand
  1. Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
    J Clin Invest. 2007 May;117(5):1147-54 PMID: 17476344
  2. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.
    Science. 2002 Sep 13;297(5588):1867-70 PMID: 12228717
  3. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.
    Lab Invest. 2003 Oct;83(10):1457-66 PMID: 14563947
  4. Modulation of tryptophan catabolism by regulatory T cells.
    Nat Immunol. 2003 Dec;4(12):1206-12 PMID: 14578884
  5. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice.
    Gastroenterology. 2003 Dec;125(6):1762-73 PMID: 14724829
  6. CTLA-4-Ig regulates tryptophan catabolism in vivo.
    Nat Immunol. 2002 Nov;3(11):1097-101 PMID: 12368911
  7. Expression of programmed death 1 ligands by murine T cells and APC.
    J Immunol. 2002 Nov 15;169(10):5538-45 PMID: 12421930
  8. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide.
    J Exp Med. 2003 Feb 17;197(4):403-11 PMID: 12591899
  9. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.
    Mol Cell. 2003 Mar;11(3):619-33 PMID: 12667446
  10. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
    Nat Med. 2003 May;9(5):562-7 PMID: 12704383
  11. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.
    J Immunol. 2003 Aug 15;171(4):1652-5 PMID: 12902462
  12. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses.
    Eur J Immunol. 2003 Oct;33(10):2773-82 PMID: 14515261
  13. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Eur J Immunol. 2004 Feb;34(2):336-44 PMID: 14768038
  14. Activation requirements for the induction of CD4+CD25+ T cell suppressor function.
    Eur J Immunol. 2004 Feb;34(2):366-76 PMID: 14768041
  15. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.
    J Immunol. 2004 Apr 1;172(7):4100-10 PMID: 15034022
  16. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.
    J Immunol. 2004 Jun 1;172(11):6519-23 PMID: 15153463
  17. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
    J Clin Invest. 2004 Jul;114(2):280-90 PMID: 15254595
  18. T cell receptor antagonist peptides induce positive selection.
    Cell. 1994 Jan 14;76(1):17-27 PMID: 8287475
  19. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
    Science. 1994 May 13;264(5161):961-5 PMID: 7513904
  20. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity.
    Nat Med. 1995 Jul;1(7):649-53 PMID: 7585145
  21. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.
    Int Immunol. 1996 May;8(5):765-72 PMID: 8671665
  22. Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo.
    Int Immunol. 1996 Mar;8(3):351-8 PMID: 8671621
  23. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.
    J Exp Med. 1998 Jul 20;188(2):287-96 PMID: 9670041
  24. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells.
    J Immunol. 1998 Aug 15;161(4):1868-74 PMID: 9712055
  25. Prevention of allogeneic fetal rejection by tryptophan catabolism.
    Science. 1998 Aug 21;281(5380):1191-3 PMID: 9712583
  26. Inhibition of T cell proliferation by macrophage tryptophan catabolism.
    J Exp Med. 1999 May 3;189(9):1363-72 PMID: 10224276
  27. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.
    Nat Immunol. 2005 Mar;6(3):280-6 PMID: 15685176
  28. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
    Nat Med. 2005 Mar;11(3):312-9 PMID: 15711557
  29. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells.
    J Exp Med. 2005 Mar 7;201(5):681-6 PMID: 15753203
  30. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
    Blood. 2005 Apr 1;105(7):2862-8 PMID: 15591121
  31. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.
    Immunity. 2005 May;22(5):633-42 PMID: 15894280
  32. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation.
    Int Immunol. 2005 Jul;17(7):909-19 PMID: 15967784
  33. Coping with stress: eIF2 kinases and translational control.
    Biochem Soc Trans. 2006 Feb;34(Pt 1):7-11 PMID: 16246168
  34. How do CD4+CD25+ regulatory T cells control autoimmunity?
    Curr Opin Immunol. 2005 Dec;17(6):638-42 PMID: 16209918
  35. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
    Curr Opin Immunol. 2006 Apr;18(2):206-13 PMID: 16464564
  36. Regulatory T cells, tumour immunity and immunotherapy.
    Nat Rev Immunol. 2006 Apr;6(4):295-307 PMID: 16557261
  37. The PD-1-PD-L pathway in immunological tolerance.
    Trends Immunol. 2006 Apr;27(4):195-201 PMID: 16500147
  38. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
    Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64 PMID: 16617117
  39. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.
    J Immunol. 2006 Jun 1;176(11):6752-61 PMID: 16709834
  40. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells.
    J Immunol. 2006 Jul 1;177(1):40-4 PMID: 16785496
  41. The tumor-draining lymph node as an immune-privileged site.
    Immunol Rev. 2006 Oct;213:146-58 PMID: 16972902
  42. Cancer despite immunosurveillance: immunoselection and immunosubversion.
    Nat Rev Immunol. 2006 Oct;6(10):715-27 PMID: 16977338
  43. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis.
    FASEB J. 2006 Nov;20(13):2384-6 PMID: 17015408
  44. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.
    Eur J Immunol. 2007 Jan;37(1):129-38 PMID: 17154262
  45. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
    Cancer Res. 2007 Jan 15;67(2):792-801 PMID: 17234791
  46. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.
    Nat Immunol. 2007 Mar;8(3):239-45 PMID: 17304234
  47. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.
    Blood. 2007 Apr 15;109(8):3351-9 PMID: 17158233
  48. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.
    J Immunol. 2000 Jan 1;164(1):183-90 PMID: 10605010
  49. Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans.
    J Exp Med. 2000 Apr 3;191(7):1241-6 PMID: 10748241
  50. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.
    Immunity. 2002 Feb;16(2):311-23 PMID: 11869690
  51. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
    Nat Med. 2003 Oct;9(10):1269-74 PMID: 14502282
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2007-09-00
Pages
2570-82
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC1940240
Subset
IM
Grants
NICHD NIH HHS · R01 HD041187 · United States
NCI NIH HHS · CA096651 · United States
NCI NIH HHS · R01 CA103320 · United States
NCI NIH HHS · R01 CA096651 · United States
NIAID NIH HHS · AI063402 · United States
NCI NIH HHS · CA103320 · United States
NICHD NIH HHS · HD41187 · United States
NIAID NIH HHS · R01 AI063402 · United States
NCI NIH HHS · R01 CA112431 · United States
NCI NIH HHS · CA112431 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com